NCT00101998 is a Phase 2 clinical trial of alvimopan in Constipation, sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).

What drugs are being tested in NCT00101998?

Interventions in NCT00101998: alvimopan, placebo.

What condition does NCT00101998 study?

NCT00101998 studies Constipation, Bowel Dysfunction.

Is NCT00101998 still recruiting?

NCT00101998 is currently completed. Last updated 30 August 2017.

Last reviewed 2017-08-30 · How we verify

NCT00101998

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication

Completed Phase 2 Last updated 30 August 2017

What this trial tests

Phase 2 trial testing alvimopan in Constipation in 233 participants. Completed in 1 May 2006.

Timeline

1 October 2003

Primary endpoint
1 May 2006

1 May 2006

Quick facts

Lead sponsor	Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	233
Start date	1 October 2003
Primary completion	1 May 2006
Estimated completion	1 May 2006
Sites	162 locations across Hong Kong, Italy, Finland, Taiwan, Poland, South Korea, Philippines, New Zealand

Drugs / interventions tested

alvimopan (ALVIMOPAN) — full drug profile →
placebo

Conditions studied

Constipation — all drugs for Constipation →
Bowel Dysfunction — all drugs for Bowel Dysfunction →

Sponsor

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) — full company profile →

Who can join

18 and older, any sex, with Constipation or Bowel Dysfunction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A multicenter study to evaluate the effectiveness and safety of multiple dosage regimens of an investigational drug for the treatment of constipation due to prescription pain medication in subjects with cancer pain. The study will require five visits over a five-week period.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.
Candy B, Jones L, Vickerstaff V, Larkin PJ, et al · · 2018 · cited 18× · PMID 29869799 · DOI 10.1002/14651858.cd006332.pub3

Verify or expand the search:

Other recruiting trials for Constipation

Currently open trials in the same condition.

NCT07462481 — Probiotic Improve Constipation · NA · recruiting
NCT07466914 — Constipation in Children With Cerebral Palsy · active not recruiting
NCT07215351 — Impact of the Inno Cleanse Dietary Supplement on Gut Health and Associated Variables in Healthy Men and Women · NA · recruiting
NCT07135362 — The Efficacy Evaluation of TCI604 Probiotic on Intestinal Function Improvement · NA · recruiting
NCT07091084 — A Study of Herbal Supplements in Cancer Survivors With Constipation · NA · recruiting

Other Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) trials

Trials by the same sponsor.

NCT02276482 — Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012) · Phase 3 · completed
NCT02387372 — Plasma Pharmacokinetics (PK) & Lung Penetration of Ceftolozane/Tazobactam in Participants With Pneumonia (MK-7625A-007) · Phase 1 · completed
NCT02341599 — Study of Pharmacokinetics of a Single IV Dose of CB-238,618 in Subjects With Varying Degrees of Renal Impairment Compare · Phase 1 · completed
NCT02266706 — Pharmacokinetic and Safety Study of Ceftolozane/Tazobactam in Pediatric Participants Receiving Antibiotic Therapy for Pr · Phase 1 · completed
NCT02070757 — Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008) · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00101998 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Last refreshed: 30 August 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00101998.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing